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Objective: Psoriasis is a chronic inflammatory skin disease that is thought to affectw2% of the global population. Psoriasis has been associated
withw30% increased risk of developing type 2 diabetes (T2D), with numerous studies reporting that psoriasis is an independent risk-factor for
T2D, separate from underlying obesity. Separately, studies of skin-specific transgenic mice have reported altered whole-body glucose ho-
meostasis in these models. These studies imply a direct role for skin inflammation and dysfunction in mediating the onset of T2D in psoriasis
patients, potentially via the endocrine effects of the skin secretome on key metabolic tissues. We used a combination of in vivo and ex vivo mouse
models and ex vivo human imiquimod (IMQ) models to investigate the effects of psoriasis-mediated changes in the skin secretome on whole-body
metabolic function.
Methods: To induce psoriatic skin inflammation, mice were topically administered 75 mg of 5% IMQ cream (or Vaseline control) to a shaved
dorsal region for 4 consecutive days. On day 5, mice were fasted for glucose and insulin tolerance testing, or sacrificed in the fed state with blood
and tissues collected for analysis. To determine effects of the skin secretome, mouse skin was collected at day 5 from IMQ mice and cultured for
24 h. Conditioned media (CM) was collected and used 1:1 with fresh media to treat mouse explant subcutaneous adipose tissue (sAT) and isolated
pancreatic islets. For human CM experiments, human skin was exposed to 5% IMQ cream for 20 min, ex vivo, to induce a psoriatic phenotype,
then cultured for 24 h. CM was collected, combined 1:1 with fresh media and used to treat human sAT ex vivo. Markers of tissue inflammation
and metabolic function were determined by qPCR. Beta cell function in isolated islets was measured by dynamic insulin secretion. Beta-cell
proliferation was determined by measurement of Ki67 immunofluorescence histochemistry and BrDU uptake, whilst islet apoptosis was
assessed by caspase 3/7 activity. All data is expressed as mean  SEM.
Results: Topical treatment with IMQ induced a psoriatic-like phenotype in mouse skin, evidenced by thickening, erythema and inflammation of
the skin. Topical IMQ treatment induced inflammation and signs of metabolic dysfunction in sub-cutaneous and epidydimal adipose tissue, liver,
skeletal muscle and gut tissue. However, consistent with islet compensation and a pre-diabetic phenotype, IMQ mice displayed improved glucose
tolerance, increased insulin and c-peptide response to glucose, and increased beta cell proliferation. Treatment of sAT with psoriatic mouse or
human skin-CM replicated the in vivo phenotype, leading to increased inflammation and metabolic dysfunction in mouse and human sAT.
Treatment of pancreatic islets with psoriatic mouse skin-CM induced increases in beta-proliferation and apoptosis, thus partially replicating the
in vivo phenotype.
Conclusions: Psoriasis-like skin inflammation induces a pre-diabetic phenotype, characterised by tissue inflammation and markers of metabolic
dysfunction, together with islet compensation in mice. The in vivo phenotype is partially replicated by exposure of sAT and pancreatic islets to
psoriatic-skin conditioned media. These results support the hypothesis that psoriatic skin inflammation, potentially via the endocrine actions of
the skin secretome, may constitute a novel pathophysiological pathway mediating the development of T2D.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Brief Communication1. INTRODUCTION
Psoriasis is a chronic inflammatory skin disease that is thought to
affect w2% of the global population, with prevalence ranging from
8.5% in Norway to 0.91% in the USA [1,2]. The pathogenesis of
psoriasis predominantly involves dysregulated Th17 pathway-
mediated inflammatory response, leading to immune cell infiltration,
epidermal hyperplasia through keratinocyte proliferation, and inflam-
mation at lesional sites [3,4]. Clinical and epidemiological studies have
demonstrated an association between psoriasis and a range of co-
morbidities including type 2 diabetes (T2D) [5e7]. For example,
psoriasis has been associated with w30% increased risk of devel-
oping T2D [7]. Patients with comorbid psoriasis diagnosed with T2D
were younger at the age of diagnosis than non-psoriasis patients [8].
Intriguingly, studies have reported that psoriasis is an independent
risk-factor for T2D and insulin resistance, separate from underlying
obesity, with the severity of psoriasis correlating with increased like-
lihood of developing T2D and the requirement of insulin therapy [5,8].
These studies imply a direct role for skin inflammation in mediating the
onset of psoriatic comorbidities. In support of this, keratinocyte-
specific SCD1 KO mice display altered glucose and lipid homeosta-
sis [9], potentially via the endocrine actions of skin-derived IL6 [10],
supporting a direct role for the skin in regulating whole-body metabolic
homeostasis.
The mechanisms underlying the effects of skin inflammation on whole-
body metabolism remain undetermined; however, the skin secretome
may play a role. The skin secretes a wide range of proteins, lipids and
small molecules [3,11e16] with potential paracrine and endocrine
effects. Many skin-derived factors, such as cytokines and glucocorti-
coids, have established metabolic functions, and altered expression
and secretion of such factors would be predicted to exert metabolic
effects [14,18e22]. Moreover, changes in the skin secretome profile
have been reported in a number of models of skin-dysfunction,
including ageing and psoriasis [23,24].
The skin is located adjacent to subcutaneous adipose tissue (sAT). sAT
dysfunction plays a key role in the development of insulin resistance
and T2D [15,25e28]. sAT is the largest and safest lipid storage depot
in the body [29]. However, due to its limited expansion capacity, the
ability of sAT to store lipids can be exceeded, resulting in ectopic lipid
deposition in metabolic organs such as the liver, skeletal muscle and
pancreas [26], which can drive metabolic dysfunction and ultimately
T2D [30]. Additionally, dysfunctional sAT secretes increased levels of
pro-inflammatory cytokines and reduced levels of insulin sensitising
adipokines and fatty acids [31e33], the combination of which further
drives metabolic dysfunction.
Since lesional psoriatic skin is located directly adjacent to the sAT, we
hypothesised that psoriatic skin inflammation and consequent alter-
ations in the skin secretome could directly impact sAT function.
Therefore, we have investigated whether skin-mediated sAT
dysfunction constitutes a novel mechanism linking psoriasis with the
development of comorbidities, including insulin resistance and T2D.
To investigate the role of the skin-sAT axis in psoriasis-mediated
development of insulin resistance and T2D, we utilised in vivo and
ex vivo mouse models and ex vivo human imiquimod (IMQ) models.
IMQ is a member of the imidazoquinolamine class of compounds and
has been found to stimulate an immune response largely through
agonistic activity on toll-like-receptor (TLR)-7 and TLR8 signalling
pathways [34,35]. The mouse IMQ model is one of the most reliable
and routinely used animal models of psoriasis [36e39], which has also
been adapted for use in human ex vivo skin.2 MOLECULAR METABOLISM 41 (2020) 101047  2020 The Authors. Published by Elsevier G2. MATERIALS AND METHODS
2.1. Mouse IMQ-model
Animal procedures were conducted under the UK Home Office Animal
Procedures (1986) Act. All work was approved by the King’s College
Animal Care and Ethics committee. C57Bl/6 mice (6e8 weeks old;
Envigo, UK) were used for this study as this strain has been reported to
present with a greater systemic inflammation in response to IMQ
[35,36,40,41]. A 4 cm2 dorsal region was shaved and depilated using
hair removal cream (Veet, Slough, UK). A daily topical dose of 75 mg
of 5% IMQ cream (3.75 mg IMQ/day; Aldara, Meda Pharma, UK) or
Vaseline equivalent (control) was applied to the shaved dorsal region
for 4 consecutive days [37]. Body weight, food intake, water intake,
and imaging for observable changes were measured daily between 9
and 10 am. Double-fold skin thickness was also measured daily, with a
mean of three readings taken each day using a thickness gauge with
0.01 mm graduation (OneCall, Farnell element14, Leeds, UK). On the
5th day, mice were either fasted for 6 h prior to the conduct of glucose
or insulin tolerance tests or sacrificed in the fed state with tissues and
serum collected.
2.2. Haemotoxylin and Eosin staining
Mouse skin sections (1 cm2) were fixed in 4% paraformaldehyde for
24 h prior to tissue processing (Leica TP 1020, Leica Biosystems,
Germany) and embedding in paraffin wax. 5 mm paraffin sections were
melted briefly on a hot plate before the slides were dewaxed using
xylene and then rehydrated using solutions of decreasing ethanol
gradient (100%e70%). The staining procedure was as follows: 5 min
immersion in Haematoxylin, 5 min in running water, three to five dips
in acid alcohol, 2 min in running water, five dips in Eosin and then 2
further minutes in running water. Following staining, the sections were
dehydrated in an increasing ethanol gradient (70%e100%). Finally,
the sections were immersed in xylene for 7 min before being mounted.
Slides were imaged with a bright field channel on a microscope
(Olympus BX40).
2.3. Human IMQ model
Human skin was obtained from corrective abdominoplasty surgery,
with written patient consent. The East London and City Health Authority
Research Ethics Committee approved the use of skin samples (09/
HO704/69). sAT was removed and skin was washed in PBS before
treatment with IMQ. 5% IMQ cream was applied topically to the skin
(Aldara, Meda Pharma, UAE) using a method adapted from Fehres et al.
(2014) [42]. Briefly, three sachets of Aldara cream were applied per
12 1 cm2 sections of skin (w3.75 mg IMQ over 1 cm2). After 20 min
of exposure to IMQ cream, excess cream was removed, and the skin
was cleaned in sterile PBS before use in conditioned media experi-
ments. Skin sections were incubated in serum-free DMEM (supple-
mented with L-glutamine and penicillin/streptomycin) at 37
̊
C and 5%
CO2 in a humidified atmosphere for 24 h, following which tissue was
snap frozen and CM collected.
2.4. Quantitative RT-PCR
Total RNA was extracted from w100 mg tissue, according to the
manufacturer’s instructions (RNeasy Lipid Mini Kit or RNeasy Mini Kit,
Qiagen, UK). Gene expression was determined by Sybr Green qRT-PCR
using DDCt methodology, normalised against GAPDH (Quantitech, UK).
Data are expressed relative to the average control treatment for each
gene. Primer sequences (Eurogentec, Southampton, UK or Quantitech,
UK) are shown in Supplemental Tables 1 and 2.mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.5. Intraperitoneal glucose and insulin tolerance tests (IPGTT &
IPITT)
Mice were fasted for 6 h and then intraperitoneally administered 2 g/kg
30% glucose solution (for GTT) or 0.75 IU/kg insulin (for ITT). Blood
glucose measurements were measured by tail prick over a 2-hour
period using an Accucheck glucose meter (Roche Diagnostics, UK).
Terminal blood samples were taken by cardiac puncture.
2.6. ELISA & Mesoscale U-Plex assays
Serum insulin and C-peptide were measure by specific ELISA (ALPCO,
United States). Serum and CM cytokine measurements were measured
using a U-PLEX TH17 Combo 2 kit (Meso Scale Diagnostics, United
States).
2.7. Immunofluorescence
Paraffin embedded sections (5 mm) of mouse pancreas were incubated
with polyclonal rabbit anti-Ki67 (Abcam, Cambridge, UK) and poly-
clonal guinea-pig anti-insulin (Agilent Pathology Solution, United
States) primary antibodies (1:200). Secondary antibodies used were
Alexa Fluor 488 donkey anti-rabbit and Alexa Fluor 594 donkey
anti-guinea pig (1:200). DAPI was also used to stain the nuclei at a
1:1000 dilution (Sigma Aldrich, UK). Sections were mounted using
Fluoromount Aqueous Mounting Medium (Dako, United States). InCell
2200 (GE Healthcare Life Sciences, UK) was used to acquire images
and analysis (cell counting and islet area calculations) was performed
using the GE InCell Developer Toolbox.
2.8. Mouse islet isolation
Mouse islets were isolated between 9 and 10 am [43]. Isolated islets
were maintained in supplemented RPMI (10% FBS; 2 mM L-glutamine,
100 U/ml penicillin/0.1 mg/ml streptomycin) at 37
̊
C and 5% CO2 in a
humidified atmosphere for up to 48 h until the experimental treatment.
2.9. Dynamic insulin secretion (perifusion)
Static or dynamic insulin secretion was assessed in response to 2 or
20 mmol/l glucose exposure, as previously described [44]. Secreted
insulin was measured by in-house I125 radioimmunoassay [45].
2.10. Caspase-Glo 3/7 apoptosis assay
Mouse islets were treated with conditioned media þ/ cytokine
cocktail (0.05 U/ml Il-1b, 1U/ml TNFa and IFNg; 48 h). Apoptosis was
determined by Caspase-Glo 3/7 luminescent assay (Promega, South-
ampton, UK).
2.11. Conditioned media (CM) experiments
For mouse CM experiments, skin obtained from IMQ- and Vaseline-
mice on day 5 following sacrifice was incubated for 24 h in DMEM
(containing 25 mmol/l glucose; 2 mmol/l glutamine, 10% FBS,
100U/ml penicillin, 100 mg/ml streptomycin). CM was collected after
24 h and combined 1:1 with fresh DMEM and used to treat control
mouse sAT or islets for 24e48 h. For human CM experiments, skin-
CM was subsequently diluted 1:1 in fresh supplemented DMEM and
used to treat sAT (100 mg; obtained from abdominoplasty), or iso-
lated mouse islets. After 24 h, CM was removed and sAT incubated
for a further 24 h in fresh DMEM before tissue collection via snap
freezing.
2.12. Data analysis
Data is expressed as mean  SEM. Significance was tested using one
or two-way ANOVA with Tukey’s or Sidak’s post-test, using GraphPad
PRISM 7 software.MOLECULAR METABOLISM 41 (2020) 101047  2020 The Authors. Published by Elsevier GmbH. This is
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3.1. Topical IMQ induced an inflammatory phenotype in mouse
skin
To examine the metabolic effects of skin inflammation, we utilised the
IMQ-mouse model. Consistent with previous studies [36,37], IMQ
treatment replicated many of the phenotypic changes observed in
human psoriasis, including erythema and scaling (Figure 1A),
increased skin-fold thickness (Figure 1B), splenomegaly (Figure 1C),
and increased epidermal thickness, measured in skin sections taken
post-sacrifice on Day 5 (Figure 1DþE). Moreover, gene expression of
inflammatory markers (IL1b, IL6, TNFa, IL17 and IL10) were elevated
in IMQ-mice compared to Vaseline controls (Figure 1FþG). In addition,
gene expression of F4/80 and Cd11b were significantly increased in
IMQ-mouse skin, indicating macrophage infiltration (Figure 1G). IMQ-
mice showed a drop in body weight for the first 2 days of treatment;
however, after 5 days, most of weight lost had been regained and there
was little difference in weight between IMQ and the Vaseline treated
controls (Supplementary Figure 1A). Similar trends were observed for
food and water intake (Supplementary Figure 1BþC).
3.2. Topical IMQ application induces inflammation and markers of
metabolic dysfunction
We hypothesised that psoriatic skin inflammation could induce inflam-
mation and metabolic dysfunction in key metabolic tissues. Given the
proximity of skin to sAT, we initially assessed whether skin inflammation
could affect sAT function through the measurement of changes in key
inflammatory and metabolic genes. Consistent with this hypothesis, an
inflammatory phenotype was observed in the sAT, denoted by significant
increases in IL1B, IL6 and IL10 gene expression in IMQ-mice compared
to Vaseline-treated controls, as well as a significant increase in the
expression of the macrophage marker F4/80 (Figure 2A). Additionally,
trends towards increased gene expression of TNFA, IL17A, CD11B (a
marker for macrophages and microglia) and Cd11c (a dendritic cell
marker) in the IMQ-treated mice were observed (Figure 2A). Conversely,
gene expression of the insulin sensitising, pro-adipogenic nuclear re-
ceptor PPARG was significantly decreased in IMQ-mouse sAT. Likewise,
sAT gene expression of GLUT4, a critical protein for insulin-stimulated
glucose uptake, was also significantly decreased (Figure 2B).
To examine the effects of skin inflammation in more distal metabolic
tissues, we assessed the expression of metabolic and pro-
inflammatory markers in epididymal adipose tissue (eAT), liver, skel-
etal muscle and gut tissue obtained from IMQ mice. Gene expression of
inflammatory markers (IL1B, IL10, F4/80, CD11C) was significantly
elevated in eAT (Figure 2C), although unlike sAT, these changes were
not associated with reduced GLUT4 or PPARG (Figure 2D). Moreover,
IMQ induced liver and skeletal muscle inflammation, characterised by
significant increases in liver IL6, TNFA, F4/80 and CD11C mRNA
(Figure 2E) and muscle IL1B, CCL2, F4/80 and CD11B mRNA
(Figure 2G) in IMQ mice compared to Vaseline control. These changes
were associated with increases in expression of liver and muscle
lipogenic genes (FASN, ACC, SREBP1, SCD1; Figure 2F,H) and marked
elevation in muscle triglyceride levels (Figure 2I). Topical IMQ also
induced significant increases in inflammatory markers in gut tissue
(Supplementary Figure 2). IMQ-treated mice displayed trends towards a
systemic inflammatory phenotype, with significantly increased serum
levels of TNFa (P < 0.001; Figure 2J) and trends towards increased
IL6, IL1B, IL17A (Figure 2KeM). Serum fatty acid and triglyceride levels
were unchanged (data not shown). Together, these data demonstrate
the skin inflammation can induce tissue and systemic inflammation and
signs of metabolic dysfunction in key metabolic tissues.an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
Figure 1: IMQ induced an inflammatory phenotype in mouse skin. C57Bl/6 mice were treated with IMQ (3.75 mg IMQ/day) or Vaseline control for 4 days. (A) Representative
Day 4 images displaying erythema and scaling (B) daily double-fold skin thickness, n ¼ 45, (C) post-sacrifice spleen weight (n ¼ 6) and (D) Representative H&E staining of mouse
skin. (E) Epidermal thickness of mouse skin calculated from HþE staining. 6 sections per mouse were stained and n ¼ 3e4 mice were used. Four measurements were taken per
image. (FeG) qPCR analysis of inflammatory gene expression in mouse skin, n ¼ 6e8. Data is expressed as mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001, vs. Vaseline control.
Figure 2: Topical IMQ application induces inflammation and markers of metabolic dysfunction in mice. Tissue and serum were obtained from C57Bl/6 mice treated with
IMQ (3.75 mg IMQ/day) or Vaseline control for 4 days. (AeH) Gene expression of inflammatory and metabolic markers was assessed by qPCR in sAT (AeB), eAT (CeD), liver (EeF)
and skeletal muscle (GeH), n ¼ 4e10; (I) Triglyceride levels were assessed in liver and skeletal muscle by colorimetric assay; (JeM) Serum cytokine concentrations were
measured by MSD U-plex assay; (J) TNFa, (K) IL6, (L) IL1b and (M) IL17A (n ¼ 12). Black bars ¼ Vaseline control, blue bars ¼ IMQ. Data is expressed as mean fold change from
controls  SEM for gene expression and mean  SEM for serum and tissue TG analysis. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Vaseline control.
Brief Communication3.3. IMQ mediates changes in whole-body glucose tolerance and
b-cell function
Since IMQ treatment induced tissue and serum changes consistent
with metabolic dysfunction, we next examined the effects of topical4 MOLECULAR METABOLISM 41 (2020) 101047  2020 The Authors. Published by Elsevier GIMQ application on whole-body glucose regulation, using glucose
tolerance tests. Fasting blood glucose (time 0) levels were unchanged
between IMQ- and Vaseline-treated mice at day 5. However, during the
IPGTT, we observed a significant reduction in blood glucose in the IMQmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mice 30 min post-glucose bolus (Figure 3A; P < 0.01). Following this,
30-minute IPGTTs were carried out with terminal blood taken at the
end time-point. During these shorter GTTs, the decrease in blood
glucose for 30 min post-glucose bolus was even more striking
(Figure 3B; P < 0.001) and terminal blood analysis demonstrated
significant increases in plasma insulin and C-peptide (Figure 3CþD;
P < 0.01), indicative of increased pancreatic b-cell insulin secretion.
We next analysed in greater depth whether changes in glucose
tolerance might be linked to altered beta-cell functional mass.
Immunofluorescence staining of IMQ- and Vaseline-treated mouse
pancreas for insulin and the proliferative marker Ki67 revealed a
significant increase in the percentage of Ki67 positive b-cells in IMQ-
mice pancreas Figure 3EeH). These changes were accompanied by, a
significant increase in cytokine-mediated apoptosis in IMQ-mouse
islets (Figure 3I). Simultaneous apoptosis and proliferation are
consistent with reports of beta-cell mass compensation during T1D
disease progression [46,47]. Islet area and b-cell number were un-
changed between the IMQ and Vaseline groups (Figure 3GþH).
Moreover, isolated IMQ-mouse islets were characterised by a quicker
response time to changes in glucose concentration and a trend to-
wards increased area under the curve for the first 30 min, suggestive
of a small but non-significant increase in 1st-phase insulin secretion
(Figure 3JþK).
Recent studies have reported that IMQ is present in serum at con-
centrations ofw75 ng/ml up to 2 days after topical application [48]. To
assess whether the effects observed in Figures 2 and 3 could be
mediated by IMQ directly, rather than through skin inflammation, weFigure 3: Glucose tolerance and b-cell proliferation are enhanced in IMQ mice. C5
Glucose response to IPGTT over (A) 2-hours and (B) 30 min. (C) Plasma insulin and (D)
administration, (n ¼ 6e7). (E) Representative immunofluorescence images of pancreata
b-cells, (G) b-cell area, and (H) b-cell number, n ¼ 7. (I) Caspase-Glo 3/7 apoptosis as
insulin secretion using isolated islets from IMQ- and Vaseline-mice (four channels were u
pooled from n ¼ 2 experiments), and (K) area under the curve for the first 30 min, n
***P < 0.001.
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(Supplementary Figure 4). However, direct IMQ treatments had no
effect on sAT gene expression isolated from CD1 and C57Bl/6 mice,
nor on insulin secretion from islets isolated from CD1 mice. Direct IMQ
treatment did cause a trend towards reduction in insulin secretion from
C57Bl/6 islets. However, these findings of reduced insulin secretion
with direct IMQ do not reflect the in vivo data, in which insulin secretion
was increased, so we remain confident that the effects observed
in vivo in the IMQ model did not occur via direct effects of absorbed
IMQ.
Together, this data suggests that psoriatic skin inflammation medi-
ates multiple effects on whole-body glucose regulation and key
metabolic tissues. These effects were unlikely to be mediated by
direct effects of absorbed IMQ, indicating a potential role for alter-
ations in the skin secretome in mediating metabolic effects of skin
inflammation.
3.4. Skin-derived factors induce sAT inflammation following IMQ
treatment of mouse and human skin
Since skin is located adjacent to sAT, we hypothesised that skin-
derived factors could particularly influence sAT function. To deter-
mine whether changes in sAT inflammation in the IMQ model occurred
via the actions of the skin secretome, we conducted conditioned media
(CM) experiments using mouse and human skin.
Skin was collected from the IMQ- and Vaseline-mice post-sacrifice at
day 5 and cultured for 24 h sAT collected from healthy control mice
was incubated with CM obtained from cultured mouse skin, to7Bl/6 mice were treated with IMQ (3.75 mg IMQ/day) or Vaseline control for 4 days.
plasma C-peptide levels from terminal blood samples taken at 30 min post-glucose
stained for insulin (red), Ki67 (green) and DAPI (blue) (F) percentage of Ki67 positive
say using IMQ- and Vaseline-mouse islets, n ¼ 4e5. (J) Dynamic glucose-stimulated
sed per treatment using islets pooled from six mice for each experiment, results are
¼ 5. Data is expressed as mean  SEM. *P < 0.05, **P < 0.01, **P < 0.01,
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5
Brief Communicationdetermine the effects of the skin secretome on healthy sAT. IMQ-skin-
CM induced a significant increase in sAT gene expression of IL1B
(P< 0.001) and non-significant increases in IL6 and TNFA (Figure 4A),
suggesting that sAT inflammation in IMQ mice is possibly driven by
actions of the skin secretome. Of note, since the skin samples used to
generate CM were taken from the lesional site of IMQ application, it is
possible that the systemic inflammatory effects of skin inflammation
could impact back on the skin, e.g., via cytokine release from inflamed
sAT, prior to skin sampling for ex vivo studies.
Next, to examine whether these effects were translatable to human
skin and sAT, we induced a psoriatic phenotype in human skin ex vivo
via exposure to IMQ. Exposure of human skin to IMQ induced a pro-
inflammatory phenotype, similar to that observed in IMQ-mouse
skin, characterised by significant increases in IL1B, IL6 and IL8
mRNA (Supplementary Figure 4). Skin CM obtained following culture of
human skin for 24 h, was then used to incubate human sAT ex vivo.
Exposure to IMQ-skin-CM led to significant increases in sAT levels of
IL1B, IL6 and IL8 (all P < 0.001) and non-significant decreases in
ADPN and GLUT4 compared to control-skin-CM (Figure 4BeC),
although there was some patient-to-patient variation within these
changes. In human sAT, IMQ-skin-CM exposure also led to small
decrease in sAT levels of phospho(Ser73)AKT, a marker of insulin
signalling (Figure 4D).Figure 4: Effects of skin-derived factors on sAT inflammation and dysfunction and p
48 h. Human sAT was incubated in human skin CM for 24 h, and then in serum-free DM
assessed by qPCR in (A) mouse sAT and (BeC) human sAT. (D) Phospho(Ser47) AKT level
mouse sAT, n ¼ 4 mice. For human results n ¼ 4 collections of sAT from four different do
Vaseline or IMQ treated mouse skin. (E) Islet apoptosis, n ¼ 11; (FeH) Beta-cell BrDU upta
were stained for insulin (red) and BrDU (green); (G) percentage of BrDU positive b-cells and
Dynamic glucose-stimulated insulin secretion using isolated islets treated with IMQ-mouse
mice. Perifusion results are presented from two pooled experiments (J) Area under the cur
Data is expressed as mean  SEM. White bars ¼ Vaseline control, blue bars ¼ IMQ. Data
Control.
6 MOLECULAR METABOLISM 41 (2020) 101047  2020 The Authors. Published by Elsevier GTogether, these data suggest that skin inflammation may be able to
induce sAT dysfunction via the actions of the skin secretome in both
mouse and human experiments.
3.5. Skin-derived factors exert mild effects on pancreatic islet
functional mass
Since beta-cell proliferation and apoptosis were altered in vivo in IMQ-
treated mice, we next examined the effects of the skin secretome on
isolated pancreatic islets. Mouse skin-CM was obtained as described
in 3.4 and used to treat isolated mouse pancreatic islets for 24 h.
Incubation of mouse islets with mouse skin-CM partially mimicked the
islet phenotype observed in IMQ mice in vivo. IMQ-skin-CM signifi-
cantly increased islet apoptosis (Figure 4E), whilst there was a small
but non-significant increase in beta-cell proliferation (as measured by
BrDU uptake) compared to CON-skin-CM (Figure 4FeG). However, in
contrast to the in vivo situation, IMQ-skin-CM reduced dynamic islet
insulin secretion and insulin content (Figure 4IeK).
Finally, we conducted preliminary analysis of the skin secretome using
a U-Plex multiplex ELISA to measure cytokine levels in Vaseline and
IMQ mouse CM. This analysis demonstrated that IL17A and IL1b levels
were non-significantly increased in IMQ-CM compared to Vaseline-CM,
whilst IL6 and TNFa were non-significantly reduced in IMQ-CM
compared to Vaseline-CM (Supplementary Figure 5).ancreatic beta-cell functional mass. Mouse sAT was incubated in mouse skin CM for
EM for a further 24 h. Gene expression of inflammatory and metabolic markers was
s were assessed using a whole-cell lysate kit (Mesoscale Discovery) in human sAT. For
nors. (EeK) Mouse islets were incubated for 24 h with skin CM collected from cultured
ke, 150e200 islets pooled from six mice were used for each treatment group. (F) Islets
(H) b-cell area. Representative images for each treatment group are also shown (F). (I)
skin CM for 24 h. Four channels were used per treatment using islets pooled from six
ve calculated from (I). (K) Islet insulin content, n ¼ 3e6 replicates per treatment group.
is expressed as mean fold change vs controls  SEM. **P < 0.01, ***P < 0.001 vs
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Together, these data suggest changes in the skin secretome occur-
ring in response to psoriatic skin inflammation may induce some of
the in vivo changes in beta-cell functional mass observed in IMQ
mice.
4. DISCUSSION
Psoriasis is reported to be an independent risk-factor for the devel-
opment of insulin resistance and T2D [4e8]. This, together with
studies showing that skin-specific transgenic mouse models display
altered whole-body glucose metabolism, suggests a direct role for the
skin, and potentially the skin-secretome, in mediating increased risk of
T2D in psoriasis [9,10]. However, the effects of skin inflammation and
the skin secretome, on glucose homeostasis are poorly characterised.
Here, using a combination of murine and human experimental models,
we provide evidence that psoriatic skin inflammation induces multiple
metabolic changes consistent with development of pre-diabetic
phenotype, potentially via the actions of the skin secretome.
Specifically, IMQ-induced psoriatic-skin inflammation induced sys-
temic inflammation with increased markers of inflammation, insulin
resistance and dyslipidaemia in key metabolic tissues including AT,
liver, muscle and gut. Consistent with onset of a pre-diabetic pheno-
type, the mice simultaneously displayed signs of islet compensation,
including increased glucose-stimulated insulin secretion, beta-cell
proliferation and improved glucose tolerance.
Importantly, we demonstrated a likely role for the skin secretome in
driving sAT dysfunction observed in IMQ mice. In both mouse and
human models, incubation of sAT with skin-CM partly recapitulated the
inflammatory and metabolic effects observed in sAT in vivo. This
suggests that the effects observed in vivo potentially occur via the
actions of factors secreted from the skin, although additional experi-
ments in which human sAT is exposed to IMQ alone are required to rule
out a direct effect of IMQ. These effects are consistent with reports that
UV light exposure, as a model of skin ageing, leads to alteration of skin
pro-inflammatory cytokine secretion, which in turn modulates sAT
function [49,50]. Other studies have reported altered sAT expression of
cholesterol efflux regulating miRNAs in biopsies taken from directlyFigure 5: Schematic of proposed hypothesis showing how skin
MOLECULAR METABOLISM 41 (2020) 101047  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.combelow psoriatic lesions compared to sAT taken from beneath non-
lesional or healthy skin [51].
The ability of the skin secretome to induce sAT dysfunction likely plays
a key role in driving IMQ-mediated changes in whole-body glucose
homeostasis via sAT inflammation and reductions in PPARG and
GLUT4 mRNA. PPARG is an anti-inflammatory, insulin sensitizing nu-
clear receptor, which also plays a key role in adipogenesis [52]. Re-
ductions in PPARG may be linked to induction of systemic inflammation
as well as ectopic lipid deposition into skeletal muscle and liver. GLUT4
encodes for insulin-regulated glucose transporter 4. Although sAT is
only responsible for w10% of prandial glucose uptake, sAT GLUT4
levels strongly correlate with insulin sensitivity, since AT GLUT4 em-
ploys a disproportionate control over whole-body glucose tolerance
[29,53]. Therefore, IMQ-mediated reductions in sAT GLUT4 are
potentially causal for changes in whole-body glucose homeostasis.
Whilst broadly consistent data was observed across the mouse and
human skin models, there are numerous differences between the
models. A key difference is the duration of IMQ exposure, in that any
effects resulting from 20 min IMQ exposure and 24 h culture in the
human skin model would likely only occur due to immediate TLR7/8
agonism [40]. For example, IMQ can directly agonise TLR7/8 on ker-
atinocytes, leading to upregulation of pro-inflammatory cytokines,
including IL8 and TNFa, via NFkB mediated mechanisms, whilst TLR7/
8 are also present on Langerhan cells [54,55].
In contrast, 4-day IMQ exposure in the in vivo model would likely
induce additional T-cell mediated mechanisms and infiltration of other
immune cell types [40]. Such differences in the mechanisms of action
may ultimately impact downstream mechanisms and outcomes.
Future studies will investigate these differences in more depth. It will
also be of interest to investigate the effects of longer IMQ exposure in
human skin models, although such experiments are constrained by the
limitations of ex vivo skin culture in which skin typically begins to lose
integrity after 24 h.
The psoriatic-skin secretome was also potentially responsible for
observed changes in pancreatic islet functional mass, with mild in-
creases in beta-cell proliferation and apoptosis. However, IMQ-skin-
CM only recapitulated some of the in vivo beta-cell changes. Thisinflammation contributes to whole-body glucose metabolism.
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beta-cell changes in the IMQ model. For example, a wide range of
bioactive proteins are secreted from adipose tissue, liver, skeletal
muscle and gut, whilst pancreatic islet hormones themselves can exert
autocrine and paracrine effects on the beta-cell. Since IMQ induced
inflammation and metabolic dysfunction in these tissues, secretion of
bioactive factors from these tissues may also change, potentially
explaining some of the observed changes in beta-cell functional mass,
which were not accounted for by the skin secretome (Figure 5).
Importantly, psoriatic skin has been shown to display an altered
secretome [23]. Whilst our data suggest a role for the skin secretome
in mediating the systemic effects of skin inflammation, the identity of
the key skin-derived factors which mediated these effects is unclear.
Our studies have identified IL1b and IL17A as cytokines which are
potentially increased in IMQ-skin CM suggesting these could play a
role in the observed phenotype. Many other inflammatory cytokines
and chemokines are reportedly secreted from sebocytes, keratinocytes
and immune cells within the skin, including, but not limited to, IL1b,
IL6, IL8, TNFa, eNAMPT, adiponectin and glucocorticoids [3,11e16].
All of these factors have established endocrine metabolic functions,
hence alterations in their secretion levels from skin would likely induce
systemic metabolic alterations [17e22]. For example, pro-
inflammatory cytokines, including IL1b and IL17A, can induce sAT
dysfunction, leading to poor lipid storage, insulin resistance and
inflammation. The effects of pro-inflammatory cytokines on islets are
more complex. Although often assumed to be deleterious to b-cell
function, inflammation can also exert beneficial effects on the
pancreatic beta-cells functional mass. For example, low concentra-
tions of IL1b have been shown to induce increased b-cell proliferation
and insulin secretion, whereas long-term IL1b exposure has a negative
impact on islet and b-cell function [17,20,56e59]. IL6 has also been
shown under some circumstances to stimulate insulin secretion [18],
whilst subsets of islet macrophages have been reported to simulta-
neously impair insulin secretion but promote beta-cell proliferation in
models of insulin resistance [60]. Future studies in which elements of
the skin secretome, such as IL1b and IL17A, are blocked in vitro and
in vivo are now required to definitively demonstrate the importance of
these factors in inducing the phenotype observed in response to IMQ.
5. CONCLUSION
In summary, we have shown that an IMQ-induced psoriatic skin-
inflammation can mediate systemic dysfunction in key metabolic tis-
sues including sAT and pancreatic islets, as well as whole-body
changes in glucose homeostasis. These changes potentially occur,
in part, due to changes in the skin secretome, supporting the hy-
pothesis that the endocrine function of skin could play an important,
previously overlooked role in whole-body metabolic homeostasis
(Figure 5). Dysfunction of this regulatory process may be a key
mediator of psoriasis co-morbidities, particularly T2D. Treatment of
skin inflammation and improvement of skin health could potentially be
used to treat or prevent psoriasis co-morbidities. Identifying the spe-
cific skin-derived factors responsible will be crucial to understanding
the inter-organ cross talk which links psoriasis and T2D. Specific skin-
derived factors could potentially be used as novel biomarkers for
predicting the risk of co-morbidity development in psoriasis patients.
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